Prostate (Neoplasia)

LE WE PMID CA

Prostate (Neoplasia)

2299

Prostata (Neubildung)

17 alpha hydroxylase 17 20 lyase

3 methyladenosine ttAutophagy

5T4 Oncotrophoblast glycoprotein

Abiraterone

Aconitase

alpha Methylacyl coenzyme A racemase

AMACR

Apoptosis

ATG5

ATG6 Beclin1

Autophagy

Bisphosphonates

BTP2 3 5 bis trifluoromethyl pyrazole derivative ttTRPC3 ttTRPC5

Cabazitaxel

Calcium (Capacitative transport)

Cardiovascular risk

Cell stress (ER stress)

Ceramide

Citric acid cycle

Colon and rectum (Neoplasia)

Curcumin

CYP17

Degarelix

Docetaxel

Econazole

Endothelin

FoxA2

GOLM1

Goserelin acetate

GSTP1 1

HIF1alpha und HIF1 (BASKET)

hVps34

IK Ca1

Immunotherapy (Adoptive cell transfer)

Interleukin24 MDA7

Interleukin32

Ion channel (Potassium)

Ion channel (TRP Family)

JAK STAT

Kidney (Neoplasia RCC)

Kidney (Neoplasm)

Klf4

Leuprorelin

LHRH

Lynch syndrome

MiRNA 205

Neoplasia (Carcinogenesis)

Neoplasia (Oncolytic virus)

Neoplasia (Screening)

Neoplasia (Tumor biology and immunology)

Neoplasia (Tumor markers)

NFAT

PCA3

Polycyclic aromatic hydrocarbons

Prostate (Anatomy)

Prostate (BASKET)

Prostate (Development)

Prostate (MRS)

Prostate (MRT)

Prostate (Neoplasia)

Prostate (Sonography)

Prostatic acid phosphatase

Radiation therapy

Radiopharmacology

Receptor (Estrogen)

Receptor (GnRH)

Rhinosporidiosis

RNA (MicroRNA)

Satraplatin

SIAH2

Sipuleucel T

Skin (Neoplasia Melanoma)

Stem cell (Neoplasia)

TMPRSS2

Transglutaminase4

Transporter (Zinc)

TRPC6

TRPM1

TRPM8

TRPV2

TRPV6

Ultrasound (Toxicity and therapeutic use)

Vaccine (Oncology)

Vanilloids

Vitamin D

Wnt beta Catenin TCF

ZD4054 ttET1RA

Zinc

ZIP1

2009 1	Degarelix and its therapeutic potential in the treatment of prostate cancer. [19503784] Clin Interv Aging 4(-): 215-23 (2009)
2006 2	Role of 5 alpha-reductase inhibitors in the management of prostate cancer. [18046919] Clin Interv Aging 1(4): 425-31 (2006)
2008 3	The top 13: what family physicians should know about prostate cancer. [18272635] Can Fam Physician 54(2): 198-203 (2008)
2009 4	Active surveillance or active treatment in localized prostate cancer? [19623304] Dtsch Arztebl Int 106(22): 371-6 (2009)
2009 5	Hormonal therapy in the elderly prostate cancer patient. [19547640] Dtsch Arztebl Int 106(14): 242-7 (2009)
1995 6	Prostatic intraepithelial neoplasia: a potential precursor lesion of prostatic adenocarcinoma. [7660673] Yonsei Med J 36(3): 215-31 (1995)
2008 7	Leuprorelin depot injection: patient considerations in the management of prostatic cancer. [18728847] Ther Clin Risk Manag 4(2): 513-26 (2008)
2007 8	Satraplatin in the treatment of hormone-refractory metastatic prostate cancer. [18473011] Ther Clin Risk Manag 3(5): 877-83 (2007)
2009 9	Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. [19128541] Health Technol Assess 13(5): iii, xi-xiii 1-219 (2009)
2007 10	A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. [17181985] Health Technol Assess 11(2): iii-iv, xv-xviii, 1-179 (2007)
2006 11	Prostate cancer treatment. The case for radical prostatectomy. [17002843] Ann R Coll Surg Engl 88(5): 439-42 (2006)
2005 12	Rectal infiltration by prostatic adenocarcinoma: a report on six patients and review of the literature. [15720916] Ann R Coll Surg Engl 87(1): 72-3 (2005)
1953 13	Benign nodular hyperplasia of the prostate; a review. [13125240] Ann R Coll Surg Engl 14(2): 92-106 (1953)
2009 14	Stroma-epithelium crosstalk in prostate cancer. [19098934] Asian J Androl 11(1): 28-35 (2009)
2009 15	Prostate cancer: diagnosis and staging. [19050692] Asian J Androl 11(1): 74-80 (2009)
2009 16	Management of locally advanced prostate cancer. [19050683] Asian J Androl 11(1): 81-7 (2009)
2010 17	Androgen receptor signaling and mutations in prostate cancer. [20711217] Asian J Androl 12(5): 639-57 (2010)
1997 18	Prostate cancer: a clinical and basic science review. [9089063] J Androl 18(1): 15-20 (1997)
1991 19	Overview of enzyme inhibitors and anti-androgens in prostatic cancer. [1769904] J Androl 12(6): 364-71 (1991)
1991 20	The emerging role of alpha antagonists in the therapy of benign prostatic hyperplasia. [1722795] J Androl 12(6): 389-94 (1991)
1991 21	The pathophysiology of benign prostatic hyperplasia. [1722791] J Androl 12(6): 356-63 (1991)
1991 22	The origin and development of benign prostatic hyperplasia. An age-dependent process. [1722790] J Androl 12(6): 348-55 (1991)
2008 23	Clinical utility of prostate carcinoma molecular diagnostic tests. [18470278] Rev Urol 10(1): 44-69 (2008)
2006 24	Treatment- and disease-related complications of prostate cancer. [17021643] Rev Urol 8 Suppl 2(-): S56-67 (2006)
2005 25	Addressing the needs of the high-risk prostate cancer patient. [16985880] Rev Urol 7 Suppl 5(-): S18-28 (2005)
2005 26	Maximum androgen blockade: a clinical update. [16985879] Rev Urol 7 Suppl 5(-): S13-7 (2005)
2004 27	A critical review of maximal androgen blockade for advanced prostate cancer. [16985916] Rev Urol 6 Suppl 8(-): S18-23 (2004)
2009 28	Brachytherapy for prostate cancer: a systematic review. [19730753] Adv Urol -(-): 327945 (2009)
2009 29	Modalities for imaging of prostate cancer. [20339583] Adv Urol -(-): 818065 (2009)
1998 30	Malignant changes in the prostate with ageing. [9883262] Br J Urol 82 Suppl 1(-): 47-58 (1998)
1997 31	The concept of evolution in the pathogenesis and treatment of prostate cancer. [9126065] Br J Urol 79 Suppl 2(-): 9-17 (1997)
2008 32	Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. [18953438] Neoplasia 10(11): 1285-94 (2008)
2007 33	Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer. [17603627] Neoplasia 9(6): 455-63 (2007)
2006 34	Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review. [17576447] Curr Oncol 13(3): 81-93 (2006)
2010 35	Update on options for treatment of metastatic castration-resistant prostate cancer. [20616956] Onco Targets Ther 3(-): 39-51 (2010)
2008 36	Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. [18456765] Ann Oncol 19 Suppl 2(-): ii45-6 (2008)
2004 37	Prostate cancer management. [15477327] Ann Oncol 15 Suppl 4(-): iv307-12 (2004)
2002 38	Treatment options in hormone resistant prostate cancer. [12401673] Ann Oncol 13 Suppl 4(-): 95-102 (2002)
2002 39	Prostate cancer: management of advanced disease. [12401672] Ann Oncol 13 Suppl 4(-): 89-94 (2002)
2002 40	Management of early prostate cancer. [12401671] Ann Oncol 13 Suppl 4(-): 83-7 (2002)
2008 41	Management of complications of prostate cancer treatment. [18502900] CA Cancer J Clin 58(4): 196-213 (2008)
2002 42	The current state of hormonal therapy for prostate cancer. [12018929] CA Cancer J Clin 52(3): 154-79 (2002)
2000 43	External beam radiation therapy for prostate cancer. [11146903] CA Cancer J Clin 50(6): 349-75; quiz 376-9 (2000)
2000 44	Modern prostate brachytherapy. [11146904] CA Cancer J Clin 50(6): 380-93 (2000)
1999 45	Contemporary results of anatomic radical prostatectomy. [11198955] CA Cancer J Clin 49(5): 282-96 (1999)
1995 46	Brachytherapy for prostate cancer. [7743420] CA Cancer J Clin 45(3): 165-78 (1995)
2008 47	An updated catalog of prostate cancer predictive tools. [18823041] Cancer 113(11): 3075-99 (2008)
2007 48	Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate. [17420979] Cancer 109(10): 2011-5 (2007)
2007 49	The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review. [17123267] Cancer 109(1): 13-24 (2007)
2005 50	Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues. [16007687] Cancer 104(5): 891-905 (2005)
2004 51	Human prostate cancer risk factors. [15495199] Cancer 101(10 Suppl): 2371-490 (2004)
2000 52	Novel strategies and therapeutics for the treatment of prostate carcinoma. [11002230] Cancer 89(6): 1329-48 (2000)
1997 53	The natural history of clinical prostate carcinoma. [9307180] Cancer 80(5): 827-33 (1997)
2010 54	Promoter hypermethylation in prostate cancer. [20861812] Cancer Control 17(4): 245-55 (2010)
2010 55	Emerging technologies in prostate cancer radiation therapy: improving the therapeutic window. [20861810] Cancer Control 17(4): 223-32 (2010)
2010 56	Premalignant and malignant prostate lesions: pathologic review. [20861809] Cancer Control 17(4): 214-22 (2010)
2007 57	High-intensity focused ultrasound (HIFU) for prostate cancer. [17615530] Cancer Control 14(3): 244-9 (2007)
2007 58	Modern brachytherapy for treatment of prostate cancer. [17615529] Cancer Control 14(3): 238-43 (2007)
2007 59	Review of primary and salvage cryoablation for prostate cancer. [17615528] Cancer Control 14(3): 231-7 (2007)
2006 60	Novel agents and targets in managing patients with metastatic prostate cancer. [16885915] Cancer Control 13(3): 194-8 (2006)
2006 61	The role of external-beam radiation therapy in the treatment of clinically localized prostate cancer. [16885914] Cancer Control 13(3): 188-93 (2006)
2004 62	Management of androgen-independent prostate cancer. [15625524] Cancer Control 11(6): 364-73 (2004)
2001 63	Prostate adenocarcinoma: cellular and molecular abnormalities. [11807425] Cancer Control 8(6): 551-61 (2001)
2001 64	NCCN: New chemotherapeutic approaches to hormone refractory prostate cancer. [11760560] Cancer Control 8(6 Suppl 2): 62-5 (2001)
2001 65	The evolving role of prostate brachytherapy. [11326171] Cancer Control 8(2): 163-70 (2001)
2001 66	Transrectal ultrasound and biopsy in the early diagnosis of prostate cancer. [11326168] Cancer Control 8(2): 141-50 (2001)
2006 67	Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. [16195239] Carcinogenesis 27(1): 1-22 (2006)
2005 68	Prostate carcinogenesis and inflammation: emerging insights. [15498784] Carcinogenesis 26(7): 1170-81 (2005)
1994 69	Prostate cancer progression. Implications of histopathology. [7977655] Am J Pathol 145(5): 983-93 (1994)
2000 70	Hormonal therapy for advanced prostate cancer. [10744596] Ann Intern Med 132(7): 584-5 (2000)
2000 71	Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. [10744594] Ann Intern Med 132(7): 566-77 (2000)
2007 72	Early versus delayed endocrine therapy for prostate cancer. [17395971] Endocr Relat Cancer 14(1): 1-11 (2007)
2005 73	Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. [15947099] Endocr Relat Cancer 12(2): 229-44 (2005)
2004 74	Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. [15369448] Endocr Relat Cancer 11(3): 459-76 (2004)
1999 75	Neuroendocrine cells in tumour growth of the prostate. [10730904] Endocr Relat Cancer 6(4): 503-19 (1999)
1999 76	Prostate cancer: molecular biology of early progression to androgen independence. [10730903] Endocr Relat Cancer 6(4): 487-502 (1999)
2000 77	Molecular genetics of prostate cancer. [11018010] Genes Dev 14(19): 2410-34 (2000)
2008 78	Approach to the prostate cancer patient with bone disease. [18178905] J Clin Endocrinol Metab 93(1): 2-7 (2008)
2001 79	Clinical review 134: The endocrinology of prostate cancer. [11502765] J Clin Endocrinol Metab 86(8): 3467-77 (2001)
2005 80	Molecular pathology of prostate cancer. [15976331] J Clin Pathol 58(7): 673-84 (2005)
2005 81	Androgen deprivation therapy for prostate cancer. [16014598] JAMA 294(2): 238-44 (2005)
2008 82	High-dose-rate brachytherapy in the curative treatment of patients with localized prostate cancer. [19046556] Mayo Clin Proc 83(12): 1364-72 (2008)
2005 83	Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease. [16007895] Mayo Clin Proc 80(7): 899-907 (2005)
2005 84	External beam radiotherapy as curative treatment of prostate cancer. [16007894] Mayo Clin Proc 80(7): 883-98 (2005)
2004 85	Tissue ablation technologies for localized prostate cancer. [15595340] Mayo Clin Proc 79(12): 1547-55 (2004)
2004 86	Minimally invasive radical prostatectomy. [15357040] Mayo Clin Proc 79(9): 1169-80 (2004)
2004 87	Unusual subtypes of prostate cancer. [14976541] Mod Pathol 17(3): 316-27 (2004)
2004 88	Gleason grading and prognostic factors in carcinoma of the prostate. [14976540] Mod Pathol 17(3): 292-306 (2004)
2004 89	Benign mimickers of prostatic adenocarcinoma. [14976539] Mod Pathol 17(3): 328-48 (2004)
2004 90	Radical prostatectomy for carcinoma of the prostate. [14765206] Mod Pathol 17(3): 349-59 (2004)
2004 91	Molecular genetics of human prostate cancer. [14752525] Mod Pathol 17(3): 380-8 (2004)
2004 92	High-grade prostatic intraepithelial neoplasia. [14739906] Mod Pathol 17(3): 360-79 (2004)
2009 93	Multidisciplinary functional MR imaging for prostate cancer. [19885309] Korean J Radiol 10(6): 535-51 (2009)
2008 94	Novel tracers and their development for the imaging of metastatic prostate cancer. [18997047] J Nucl Med 49(12): 2031-41 (2008)
2003 95	PET imaging of prostate cancer with 11C-acetate. [12679399] J Nucl Med 44(4): 556-8 (2003)
2007 96	Functional MR imaging of prostate cancer. [17234999] Radiographics 27(1): 63-75; discussion 75-7 (2007)
2004 97	Complications of prostate cancer treatment: spectrum of imaging findings. [15486240] Radiographics 24 Suppl 1(-): S181-94 (2004)
2004 98	Pretreatment evaluation of prostate cancer: role of MR imaging and 1H MR spectroscopy. [15486239] Radiographics 24 Suppl 1(-): S167-80 (2004)
2001 99	Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer. [11314451] CMAJ 164(7): 975-81 (2001)
1999 100	Prostatic carcinoma. [9925399] Radiographics 19(1): 185-203 (1999)
1990 101	Cystic lesions of the prostate. [1696019] Radiographics 10(4): 635-50 (1990)
2008 102	Pictorial review: Unusual tumours involving the prostate: radiological-pathological findings. [18662962] Br J Radiol 81(971): 907-15 (2008)
2007 103	Imaging prostate cancer: a multidisciplinary perspective. [17392247] Radiology 243(1): 28-53 (2007)
2006 104	Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. [16569788] Radiology 239(3): 784-92 (2006)
2005 105	Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. [15867098] Endocr Rev 26(3): 361-79 (2005)
2004 106	Androgen receptor in prostate cancer. [15082523] Endocr Rev 25(2): 276-308 (2004)
2009 107	Vanilloid-mediated apoptosis in prostate cancer cells through a TRPV-1 dependent and a TRPV-1-independent mechanism. [19705615] Acta Biomed 80(1): 13-20 (2009)
2008 108	Iodine-125 seed implantation (permanent brachytherapy) for clinically localized prostate cancer. [18323866] Acta Med Okayama 62(1): 9-13 (2008)
2011 109	[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. [21757258] Actas Urol Esp 35(10): 565-79 (2011)
2010 110	Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. [20555062] Ann Oncol 21 Suppl 5(-): v129-33 (2010)
2010 111	Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. [19633053] Ann Oncol 21(2): 312-8 (2010)
2010 112	Horizon scanning for novel therapeutics for the treatment of prostate cancer. [20943642] Ann Oncol 21 Suppl 7(-): vii43-55 (2010)
2005 113	Hormonotherapy of advanced prostate cancer. [15923436] Ann Oncol 16 Suppl 4(-): iv80-84 (2005)
2009 114	Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. [19454471] Ann Oncol 20 Suppl 4(-): 76-8 (2009)
2009 115	Challenges in clinical prostate cancer: role of imaging. [19457806] AJR Am J Roentgenol 192(6): 1455-70 (2009)
2009 116	Imaging localized prostate cancer: current approaches and new developments. [19457807] AJR Am J Roentgenol 192(6): 1471-80 (2009)
2004 117	Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S). [15323145] Am J Clin Pathol 122(2): 275-89 (2004)
2011 118	Targeting transcription factor Stat5a/b as a therapeutic strategy for prostate cancer. [21416055] Am J Transl Res 3(2): 133-8 (2011)
2009 119	Neuroendocrine differentiation in prostate cancer. [19956427] Am J Transl Res 1(2): 148-62 (2009)
2010 120	Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. [20843937] BMJ 341(): c4543 (2010)
2011 121	A practical guide to prostate cancer diagnosis and management. [21536828] Cleve Clin J Med 78(5): 321-31 (2011)
2010 122	New developments in the medical management of prostate cancer. [20042563] Mayo Clin Proc 85(1): 77-86 (2010)
2007 123	Prostate cancer: a practical approach to current management of recurrent disease. [17290734] Mayo Clin Proc 82(2): 243-9 (2007)
2007 124	Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide. [17507719] Radiology 244(1): 196-204 (2007)
2007 125	Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. [17890357] Radiology 245(2): 499-506 (2007)
2008 126	Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging. [18024434] Radiology 246(1): 177-84 (2008)
2011 127	Pseudosarcomatous fibromyxoid tumor of the prostate. [21552766] ScientificWorldJournal 11(-): 1027-30 (2011)
2011 128	Methods to predict and lower the risk of prostate cancer. [21479345] ScientificWorldJournal 11(-): 742-8 (2011)
2010 129	PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer. [20890581] ScientificWorldJournal 10(-): 1919-31 (2010)
2010 130	Stereotactic body radiation therapy (SBRT) for genitourinary malignancies. [20875347] Discov Med 10(52): 255-62 (2010)
2005 131	Endocrine approaches in the therapy of prostate carcinoma. [15790600] Hum Reprod Update 11(3): 309-17 (2005)
2010 132	New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK. [20423984] Clin Cancer Res 16(13): 3322-8 (2010)
2009 133	Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. [19638458] Clin Cancer Res 15(15): 4792-8 (2009)
2009 134	Targeting the PI3K/AKT pathway for the treatment of prostate cancer. [19638457] Clin Cancer Res 15(15): 4799-805 (2009)
2009 135	Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. [19684076] Oncologist 14(8): 816-27 (2009)
2008 136	Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer. [18278811] Cancer 112(8): 1660-71 (2008)
2006 137	Treatment options in lymph node-positive prostate cancer. [16700035] Cancer 106(12): 2531-9 (2006)
2007 138	Pten inactivation and the emergence of androgen-independent prostate cancer. [17638861] Cancer Res 67(14): 6535-8 (2007)
2009 139	Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. [19509232] Cancer Res 69(12): 4937-40 (2009)
2009 140	Concepts of epigenetics in prostate cancer development. [19002169] Br J Cancer 100(2): 240-5 (2009)
2008 141	Emerging biomarkers for the diagnosis and prognosis of prostate cancer. [18927246] Clin Chem 54(12): 1951-60 (2008)
2011 142	Radical prostatectomy versus watchful waiting in early prostate cancer. [21542742] N Engl J Med 364(18): 1708-17 (2011)
2010 143	Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. [21029717] Health Technol Assess 14(47): 1-108, iii-iv (2010)
2009 144	Molecular mechanisms of castration-resistant prostate cancer progression. [19903068] Future Oncol 5(9): 1403-13 (2009)
2007 145	My approach to intraductal lesions of the prostate gland. [17237185] J Clin Pathol 60(8): 856-65 (2007)
2007 146	TMPRSS2-ETS fusion prostate cancer: biological and clinical implications. [17965219] J Clin Pathol 60(11): 1185-6 (2007)
2007 147	Spindle cell lesions of the adult prostate. [17170745] Mod Pathol 20(1): 148-58 (2007)
2007 148	Pathogenesis of prostate cancer and hormone refractory prostate cancer. [19675761] Indian J Urol 23(1): 35-42 (2007)
2007 149	Update in palliative management of hormone refractory cancer of prostate. [19675762] Indian J Urol 23(1): 43-50 (2007)
2007 150	Use of bisphosphonates in prostate cancer: Current status. [19675763] Indian J Urol 23(1): 51-4 (2007)
2007 151	New therapeutic targets in the treatment of prostate cancer. [19675766] Indian J Urol 23(1): 61-6 (2007)
2007 152	Treatment algorithm in hormone-resistant prostate cancer: Practical guidelines. [19675767] Indian J Urol 23(1): 67-9 (2007)
2009 153	Etiopathogenesis of benign prostatic hypeprlasia. [19881121] Indian J Urol 25(3): 312-7 (2009)
2010 154	The Siah2-HIF-FoxA2 axis in prostate cancer – new markers and therapeutic opportunities. [21037926] Oncotarget 1(5): 379-85 (2010)
2006 155	Polycyclic aromatic hydrocarbon-DNA adduct formation in prostate carcinogenesis. [16154258] Cancer Lett 239(2): 157-67 (2006)
2011 156	Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. [21149473] J Nucl Med 52(1): 81-9 (2011)
2009 157	Epigenetic alterations in human prostate cancers. [19520778] Endocrinology 150(9): 3991-4002 (2009)
2007 158	Zinc as an anti-tumor agent in prostate cancer and in other cancers. [17400177] Arch Biochem Biophys 463(2): 211-7 (2007)
2002 159	Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. [11914183] Endocr Relat Cancer 9(1): 61-73 (2002)
2011 160	Pathways of chemotherapy resistance in castration-resistant prostate cancer. [21565970] Endocr Relat Cancer 18(4): R103-23 (2011)
2010 161	An update on androgen deprivation therapy for prostate cancer. [20861285] Endocr Relat Cancer 17(4): R305-15 (2010)
2010 162	MicroRNAs and prostate cancer. [19779034] Endocr Relat Cancer 17(1): F1-17 (2010)
2007 163	Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. [17914087] Endocr Relat Cancer 14(3): 531-47 (2007)
2006 164	High-intensity focused ultrasound: a potential salvage treatment for recurrent prostate cancer following radiotherapy. [16831068] Expert Rev Anticancer Ther 6(7): 969-70 (2006)
2010 165	MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. [20737563] Cancer 116(24): 5637-49 (2010)
2010 166	Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24. [20406981] Cancer Res 70(9): 3667-76 (2010)
2011 167	Prostate transglutaminase (TGase-4) antagonizes the anti-tumour action of MDA-7/IL-24 in prostate cancer. [21524313] J Transl Med 9(): 49 (2011)
2010 168	Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach. [19888195] Mol Ther 18(2): 295-306 (2010)
2011 169	5-α reductase inhibitors and prostate cancer prevention: where do we turn now? [21920036] BMC Med 9(-): 105 (2011)
2011 170	Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. [21448449] Drug Des Devel Ther 5(-): 117-24 (2011)
2010 171	Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. [20138542] Trends Endocrinol Metab 21(5): 315-24 (2010)
2011 172	Wnt signaling in prostate development and carcinogenesis. [21475372] Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 155(1): 11-8 (2011)
2011 173	TRP channels in prostate cancer: the good, the bad and the ugly? [21623387] Asian J Androl 13(5): 673-6 (2011)
2003 174	Store-operated Ca2+ current in prostate cancer epithelial cells. Role of endogenous Ca2+ transporter type 1. [12584203] J Biol Chem 278(17): 15381-9 (2003)
2001 175	Expression of CaT-like, a novel calcium-selective channel, correlates with the malignancy of prostate cancer. [11278579] J Biol Chem 276(22): 19461-8 (2001)
2004 176	TRPV6 and prostate cancer: cancer growth beyond the prostate correlates with increased TRPV6 Ca2+ channel expression. [15336984] Biochem Biophys Res Commun 322(4): 1359-63 (2004)
2007 177	TRP channels in cancer. [17616360] Biochim Biophys Acta 1772(8): 937-46 (2007)
2006 178	TRPV6 potentiates calcium-dependent cell proliferation. [16356545] Cell Calcium 39(2): 163-73 (2006)
2003 179	Store-operated Ca2+ channels in prostate cancer epithelial cells: function, regulation, and role in carcinogenesis. [12765682] Cell Calcium 33(5-6): 357-73 (2003)
2011 180	TRPV6 determines the effect of vitamin D3 on prostate cancer cell growth. [21347289] PLoS One 6(2): e16856 (2011)
2010 181	TRP channels in human prostate. [20730379] ScientificWorldJournal 10(): 1597-611 (2010)
2009 182	Intermediate-conductance Ca2+-activated K+ channels (IKCa1) regulate human prostate cancer cell proliferation through a close control of calcium entry. [19270724] Oncogene 28(15): 1792-806 (2009)
2007 183	TRPV6 channel controls prostate cancer cell proliferation via Ca(2+)/NFAT-dependent pathways. [17533368] Oncogene 26(52): 7380-5 (2007)
2003 184	Expression of the Ca2+-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression. [14586412] Oncogene 22(49): 7858-61 (2003)
2011 185	Chemical inhibitors of the calcium entry channel TRPV6. [21057859] Pharm Res 28(2): 322-30 (2011)
2011 186	Value of ultrasound elastography in the diagnosis and management of prostate carcinoma. [21390343] Med Ultrason 13(1): 45-53 (2011)
2011 187	Real-time ultrasound prostate elastography. An increasing role in prostate cancer detection? [21390335] Med Ultrason 13(1): 3-4 (2011)
2010 188	Prostate lesions with cribriform / pseudocribriform pattern. [20809015] Rom J Morphol Embryol 51(3): 413-25 (2010)
2010 189	Cellular interactions in prostate cancer genesis and dissemination. Looking beyond the obvious. [20809016] Rom J Morphol Embryol 51(3): 427-35 (2010)
2010 190	Neuroendocrine transdifferentiation of prostate carcinoma cells and its prognostic significance. [20191113] Rom J Morphol Embryol 51(1): 7-12 (2010)
2011 191	A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy. [21874106] Curr Oncol 18(4): e163-72 (2011)
2011 192	Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. [21513551] J Hematol Oncol 4(-): 18 (2011)
2008 193	Recurrent gene fusions in prostate cancer. [18563191] Nat Rev Cancer 8(7): 497-511 (2008)
2010 194	American Cancer Society guideline for the early detection of prostate cancer: update 2010. [20200110] CA Cancer J Clin 60(2): 70-98 (2010)
2010 195	Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. [20124400] CA Cancer J Clin 60(3): 194-201 (2010)
2009 196	High-grade prostatic intraepithelial neoplasia of the prostate: the precursor lesion of prostate cancer. [19158990] Int J Clin Exp Pathol 2(4): 327-38 (2009)
2009 197	Molecular markers in prostate cancer. Part II: potential roles in management. [19050689] Asian J Androl 11(1): 22-7 (2009)
2009 198	Molecular markers in prostate cancer. Part I: predicting lethality. [19050690] Asian J Androl 11(1): 14-21 (2009)
2010 199	Histological changes in the human prostate after radiotherapy and salvage high intensity focused ultrasound. [20694085] Can Urol Assoc J 4(4): E100-2 (2010)
2011 200	Emerging novel therapies in the treatment of castrate-resistant prostate cancer. [21470540] Can Urol Assoc J 5(2): 120-33 (2011)
2011 201	Prostate cancer screening: Canadian guidelines 2011. [21801679] Can Urol Assoc J 5(4): 235-40 (2011)
2010 202	The novel prostate cancer antigen 3 (PCA3) biomarker. [21176272] Int Braz J Urol 36(6): 665-8; discussion 669 (2010)
2009 203	T2-Weighted endorectal magnetic resonance imaging of prostate cancer after external beam radiation therapy. [19409121] Int Braz J Urol 35(2): 171-80; discussion 181-2 (2009)
2009 204	Anti-neoplastic activity of curcumin in PCa. [19538760] Int Braz J Urol 35(3): 254-5 (2009)
2011 205	Diagnostic dilemmas of squamous differentiation in prostate carcinoma case report and review of the literature. [21627811] Diagn Pathol 6(-): 46 (2011)
2011 206	Cardiovascular risk during hormonal treatment in patients with prostate cancer. [21448299] Cancer Manag Res 3(-): 49-55 (2011)
2011 207	Chemoprevention of prostate cancer with nutrients and supplements. [21629831] Cancer Manag Res 3(-): 91-100 (2011)
2010 208	Evaluation of degarelix in the management of prostate cancer. [21188095] Cancer Manag Res 2(-): 39-52 (2010)
2009 209	Update on the management of prostate cancer with goserelin acetate: patient perspectives. [21188128] Cancer Manag Res 1(-): 99-105 (2009)
2011 210	Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: an insight for oncologists. [21789160] Ther Adv Med Oncol 3(2): 101-8 (2011)
2007 211	Minimally invasive approaches to prostate cancer: a review of the current literature. [17987573] Urol J 4(3): 130-7 (2007)
2007 212	Androgen deprivation therapy for prostate cancer: new concepts and concerns. [17940447] Curr Opin Endocrinol Diabetes Obes 14(3): 247-54 (2007)
2007 213	Current standard and investigational approaches to the management of hormone-refractory prostate cancer. [17387372] Rev Urol 9 Suppl 1(-): S9-S19 (2007)
2007 214	High-risk, clinically localized prostate cancer: is monotherapy adequate? [17554402] Rev Urol 9 Suppl 2(-): S19-27 (2007)
2008 215	ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer. [18616419] Expert Opin Investig Drugs 17(8): 1237-45 (2008)
2007 216	The median non-prostate cancer survival is more than 10 years for men up to age 80 years who are selected and receive curative radiation treatment for prostate cancer. [17511871] Radiat Oncol 2(-): 17 (2007)
2011 217	Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T? [22084621] Clin Med Insights Oncol 5(-): 325-32 (2011)
2011 218	Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer. [21695098] Clin Med Insights Oncol 5(-): 163-9 (2011)
2004 219	The role of alpha-blockers in the management of prostate cancer. [15163273] Expert Opin Pharmacother 5(6): 1279-85 (2004)
2010 220	Angiogenesis inhibitors in the treatment of prostate cancer. [20088745] Expert Opin Pharmacother 11(2): 233-47 (2010)
2010 221	Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial. [20964826] BMC Cancer 10(-): 572 (2010)
2010 222	Prioritizing genes associated with prostate cancer development. [21044312] BMC Cancer 10(-): 599 (2010)
2011 223	Saudi Oncology Society clinical management guidelines for prostate cancer. [21673847] Urol Ann 3 Suppl(-): S10-6 (2011)
2011 224	An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. [21904569] Ther Adv Urol 3(3): 127-40 (2011)
2010 225	Novel diagnostic biomarkers for prostate cancer. [20975847] J Cancer 1(-): 150-77 (2010)
2010 226	Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment. [20130444] Pharmacology 85(2): 110-20 (2010)
2011 227	Imaging in prostate cancer diagnosis: present role and future perspectives. [21372554] Urol Int 86(4): 373-82 (2011)
2011 228	Current treatment strategies for castration-resistant prostate cancer. [21461278] Korean J Urol 52(3): 157-65 (2011)
2010 229	Radical prostatectomy for high-risk prostate cancer. [19841101] Jpn J Clin Oncol 40(1): 3-9 (2010)
2009 230	Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer. [19318948] Curr Opin Urol 19(3): 221-6 (2009)
2009 231	Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET. [19434102] Nat Rev Urol 6(6): 317-23 (2009)
2009 232	Management of complications of androgen deprivation therapy in the older man. [18952456] Crit Rev Oncol Hematol 70(3): 235-55 (2009)
2008 233	The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. [18280514] J Urol 179(4): 1235-42 (2008)
2007 234	Low risk prostate cancer in men under age 65: the case for definitive treatment. [18047962] Urol Oncol 25(6): 510-4 (2007)
2009 235	Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. [19414113] Urol Oncol 27(3): 251-7 (2009)
2009 236	Identification, characterization, and biological relevance of prostate cancer stem cells from clinical specimens. [19414117] Urol Oncol 27(3): 301-3 (2009)
2011 237	Overall and worst gleason scores are equally good predictors of prostate cancer progression. [21978318] BMC Urol 11(-): 21 (2011)
2009 238	A systematic review of the diagnostic accuracy of prostate specific antigen. [19744336] BMC Urol 9(-): 14 (2009)
2010 239	A new algorithm in patients with elevated and/or rising prostate-specific antigen level, minor lower urinary tract symptoms, and negative multisite prostate biopsies. [19496018] Int Urol Nephrol 42(1): 29-38 (2010)
2009 240	New horizons in prostate cancer imaging. [18993004] Eur J Radiol 70(2): 212-26 (2009)
2009 241	Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. [18952365] Eur Urol 55(3): 575-90 (2009)
2011 242	Hereditary prostate cancer as a feature of Lynch syndrome. [20872076] Fam Cancer 10(1): 37-42 (2011)
2011 243	Screening for prostate cancer: the current evidence and guidelines controversy. [22018148] Can J Urol 18(5): 5875-83 (2011)
2009 244	New therapeutic agents for castration-refractory prostate cancer. [19692323] Clin Genitourin Cancer 7(2): E4-6 (2009)
2009 245	Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. [19796750] Lancet Oncol 10(10): 981-91 (2009)
2008 246	The discovery and application of gene fusions in prostate cancer. [18422767] BJU Int 102(3): 276-82 (2008)
2011 247	Role of signaling transduction pathways in development of castration-resistant prostate cancer. [22110995] Prostate Cancer 2011(-): 647987 (2011)
2009 248	The role of androgen receptor mutations in prostate cancer progression. [19721807] Curr Genomics 10(1): 18-25 (2009)
2011 249	Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target. [21504942] J Mol Endocrinol 47(1): R25-41 (2011)
2008 250	The role of estrogens and estrogen receptors in normal prostate growth and disease. [18093629] Steroids 73(3): 233-44 (2008)
2011 251	An update on TroVax for the treatment of progressive castration-resistant prostate cancer. [21691576] Onco Targets Ther 4(-): 33-41 (2011)
2011 252	Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments. [21792315] Onco Targets Ther 4(-): 79-96 (2011)
2010 253	Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis. [20501771] Cancer Epidemiol Biomarkers Prev 19(6): 1632-42 (2010)
2010 254	Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration. [21159640] Cancer Res 70(24): 10182-91 (2010)
2011 255	Targeting tyrosine kinases and autophagy in prostate cancer. [21350583] Horm Cancer 2(1): 38-46 (2011)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Prostate (Neoplasia).php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Prostate (Neoplasia).php on line 92